Payment overview · 2025
General Payments
$1,657.96
73 reported records · 27 companies
Healthcare provider profile · identity verified
Dane J Dickson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · REXBURG, ID · NPI 1669497194
Verified facts
What the public records show
CMS Open Payments records show Dane J Dickson, MD received $1,657.96 in general payments during 2025 across 73 reported records.
PFIZER INC. accounted for 11.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 51 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Erleada, Xtandi.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Erleada by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $196.97 | 11.9% | 14 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $158.91 | 9.6% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $158.83 | 9.6% | 6 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $143.35 | 8.7% | 3 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $121.59 | 7.3% | 2 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $107.18 | 6.5% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $98.24 | 5.9% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $63.65 | 3.8% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $53.64 | 3.2% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $52.07 | 3.1% | 3 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $46.79 | 2.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.11 | 2.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.24 | 2.4% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $39.05 | 2.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.85 | 2.3% | 2 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.68 | 2.3% | 2 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $33.45 | 2.0% | 1 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $32.84 | 2.0% | 1 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $28.45 | 1.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.80 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.67 | 1.4% | 1 | 2025 |
| Iovance Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $22.36 | 1.4% | 1 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.67 | 1.3% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $20.07 | 1.2% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.18 | 1.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $17.09 | 1.0% | 1 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $15.23 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,457.98 | 71 |
| Education | $199.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $143.35 | 3 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $121.59 | 2 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $119.03 | 5 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $97.01 | 3 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $81.69 | 4 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $71.19 | 5 | 2025 |
Source payment records
|
|||||
| Zoladex Normalized: zoladex |
Drug | TerSera Therapeutics LLC | $71.06 | 3 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $53.64 | 3 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $53.64 | 3 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $52.07 | 3 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $51.04 | 5 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme LLC | $49.53 | 3 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $46.79 | 2 | 2025 |
Source payment records
|
|||||
| TIVDAK Normalized: tivdak |
Biological | PFIZER INC. | $41.95 | 2 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $40.88 | 2 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $40.88 | 2 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $40.24 | 2 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $40.24 | 2 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $40.06 | 3 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC., Sumitomo Pharma America, Inc. | $39.57 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Biological, Drug | ABBVIE INC., Genentech USA, Inc. | $38.89 | 2 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $38.85 | 2 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| Quzyttir Normalized: quzyttir |
Drug | TerSera Therapeutics LLC | $36.12 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological | Legend Biotech USA Inc. | $33.45 | 1 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $32.84 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | PFIZER INC. | $31.13 | 2 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | PFIZER INC. | $31.13 | 2 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $28.45 | 1 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| Amtagvi Normalized: amtagvi |
Drug | Iovance Biotherapeutics, Inc. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| REVUFORJ Normalized: revuforj |
Drug | Syndax Pharmaceuticals, Inc. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| EMRELIS Normalized: emrelis |
Drug | ABBVIE INC. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| CERDELGA Normalized: cerdelga |
Drug | GENZYME CORPORATION | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| CEREZYME Normalized: cerezyme |
Biological | GENZYME CORPORATION | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| Optune Lua (NovoTTF-200T) Normalized: optune lua novottf 200t |
Device | Novocure Inc. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ERLEADA erleada |
2025 | Erleada | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 58 | 14 |
| Tamoxifen Citrate | Tamoxifen Citrate | 57 | suppressed |
| Letrozole | Letrozole | 29 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Omeprazole | Omeprazole | 18 | suppressed |
| Lenalidomide | Lenalidomide | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Xtandi | Enzalutamide | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Erleada | Apalutamide | 11 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,657.96 · 73 records | PFIZER INC. | ADCETRIS, AKEEGA, Amtagvi, BALVERSA, BRAFTOVI, CARVYKTI, CERDELGA, CEREZYME, ELREXFIO, EMRELIS, ERLEADA, Enhertu, FOTIVDA, Gavreto, IBRANCE, IMFINZI, INJECTAFER, JAKAFI, JAYPIRCA, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LYNPARZA, MEKTOVI, MONJUVI, OGSIVEO, OPDIVO, ORGOVYX, Optune Lua (NovoTTF-200T), PADCEV, PROVENGE, Quzyttir, REBLOZYL, REVUFORJ, RYBREVANT, RYTELO, Rezlidhia, SARCLISA, SYNCHROMEDII, TALZENNA, TAVALISSE, TIVDAK, TUKYSA, Trodelvy, VENCLEXTA, VERZENIO, Vanflyta, WELIREG, XTANDI, Zoladex, clonoSEQ | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Erleada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Biotech, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error